8/17/2009

The HHS issued a subpoena to Gilead Sciences asking for documents regarding the development, marketing and sales of Ranexa, a chronic angina drug developed by the Gilead-acquired firm CV Therapeutics. A company spokeswoman did not provide further information about the subpoena.

Related Summaries